Skip to main content
spacbrain

Aspire Biopharma Holdings

Closed (deSPAC)

Health Care · biopharmaceutical product development

What it is
Biopharma, Inc
What it’s doing now
Merging with PowerUp Acquisition Corp. (PWUP) — closed (despac).
What you should know
The deal carries a $5M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

Biopharma, Inc . Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com .

Source: S-4/A, accession 0001493152-25-001441

What the company says about itself

Web research — not audited

Aspire Biopharma Holdings Inc. is an early-stage technical company developing and marketing disruptive sublingual drug delivery technology. Originally formed in September 2021, the company uses patent-pending nano technology and micelle-based formulations to enable rapid absorption of drugs and supplements under the tongue, bypassing the gastrointestinal tract. Its launch product is sublingual aspirin targeting cardiology and stroke emergencies, acute pain management, and anti-inflammatory needs, positioned as a safe opioid alternative. The company has filed two USPTO patent applications and completed clinical trials for its sublingual aspirin product in July 2025.

Markets:
Pharmaceuticals | Drug Delivery Technology | Pain Management | Cardiology | Anti-inflammatory
Products:
Sublingual aspirin | Sublingual drug delivery technology | Micelle-based high-dose aspirin delivery system
What our web check found

[WEB-INTEL 2026-08-26] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The Business Combination was approved by PowerUp Acquisition Corp. stockholders on January 31, 2025, and it closed on February 17, 2025." [https://www.nasdaq.com/press-release/aspire-biopharma-holdings-inc-announces-public-listing-nasdaq-2025-02-19] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "This is the same deal with Min-cash condition $5M stated" [https://spacbrain.com/spac/PWUP/deal]

Source: https://aspirebiolabs.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Aspire Biopharma Holdings is merging with PowerUp Acquisition Corp. (PWUP) currently marked Closed (deSPAC).

Headline equity value—
Minimum cash to close$5M

Structure per SEC accession(s) 0001493152-24-003997. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Aspire Biopharma Holdings going public?

Aspire Biopharma Holdings has an approved merger with the SPAC PowerUp Acquisition Corp. (PWUP). Deal status: Closed (deSPAC).

Does Aspire Biopharma Holdings have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals
Same sponsor’s other SPACs
  • AEHA — Aesther Healthcare Acquisition Corp. · Closed (deSPAC)